

be present in the dialysis fluid at about 1-1,000, 5-750, 20-500, but more preferably 50-500 nM.-

In the claims:

Please cancel ~~claims~~ 4 and 17.

Please amend claims 1-3, 5-6, 8, 16-18, 21 and 23 as follows:

--1. (Amended) A method of treating permeability failure in a subject, comprising:
introducing into said subject a peritoneal dialysis fluid which includes a specific inhibitor of
a PKC, thereby treating said subject.

2. (Amended) The method of claim 1, wherein said specific inhibitor is a specific
inhibitor of PKC β .

3. (Amended) The method of claim 1, wherein said specific inhibitor is selected
from the group consisting of: a specific inhibitor of a PKC β , a specific inhibitor of PKC γ ,
and a specific inhibitor of PKC δ .

4. (Cancel) The method of claim 2, wherein said inhibitor is an inhibitor of PKC β .

5. (Amended) The method of claim 1, wherein said specific inhibitor is an inhibitor
of PKC β 1.

6. (Amended) The method of claim 2, wherein said inhibitor is a bis (indolyl)
maleimide.

7. (Reiterated) The method of claim 6, wherein said inhibitor is LY333531.

8. (Amended) The method of claim 7, wherein said LY333531 is present in said
dialysis fluid at about 1-1,000 nM.

9. (Reiterated) The method of claim 1, wherein said dialysis fluid has a
concentration of glucose of about 200nM.

10. (Reiterated) The method of claim 1, wherein said subject has previously received peritoneal dialysis.

11. (Reiterated) The method of claim 1, wherein said subject has been a peritoneal dialysis patient for at least 2 to 24 months.

12. (Reiterated) The method of claim 1, wherein said subject has already developed permeability disjunction.

13. (Reiterated) The method of claim 1, wherein said subject has not yet developed permeability disjunction.

14. (Reiterated) The method of claim 1, wherein said subject is at risk for renal failure.

15. (Reiterated) The method of claim 14, wherein said subject is in end-stage renal failure.

AG 16. (Amended) A peritoneal dialysis fluid comprising a specific inhibitor of a PKC.

17. (Cancel) The dialysis fluid of claim 16, wherein said inhibitor is a specific inhibitor of PKC.

A7 18. (Amended) The dialysis fluid of claim 16, wherein said specific inhibitor is an inhibitor of PKC β .

19. (Reiterated) The dialysis fluid of claim 18, wherein said inhibitor is a bis (indolyl) maleimide.

20. (Reiterated) The dialysis fluid of claim 19, wherein said inhibitor is LY333531.

AS 21. (Amended) The dialysis fluid of claim 20, wherein said LY333531 is present in said dialysis fluid at about 1-1,000 nM.

22. (Reiterated) The dialysis fluid of claim 16, wherein said dialysis fluid has a concentration of glucose of about 200nM.

A9 23. (Amended) A method of making an improved peritoneal dialysis fluid, comprising: providing a peritoneal dialysis fluid; and adding to that fluid a specific inhibitor of a PKC, to thereby provide an improved dialysis fluid.

24. (Reiterated) The method of claim 23, wherein said inhibitor is LY333531.--